Cover Image
Market Research Report

Global Cytomegalovirus (CMV) Therapeutics Market 2019-2023

Published by TechNavio (Infiniti Research Ltd.) Product code 823156
Published Content info 121 Pages
Delivery time: 1-2 business days
Price
Back to Top
Global Cytomegalovirus (CMV) Therapeutics Market 2019-2023
Published: March 29, 2019 Content info: 121 Pages
Description

About this market

High prevalence of congenital CMV will drive the CMV therapeutics market growth in the forthcoming years. Vendors are increasingly conducting researches to launch novel therapeutics including vaccines that can be administered in newborns. This will also prevent the progression of CMV while catering to the huge unmet need in the market. As a result, the high prevalence of congenital CMV will eventually drive the CMV therapeutics market growth during the next few years. Technavio's analysts have predicted that the cytomegalovirus (CMV) therapeutics market will register a CAGR of nearly 5% by 2023.

Market Overview

Recurring nature of the disease

One of the growth drivers of the global cytomegalovirus (CMV) therapeutics market is the recurring nature of the disease. The recurring nature of CMV and the potential risk of the indications caused by the disease will significantly increase sales of CMV therapeutics, which will drive the growth of the market.

Asymptomatic nature of the disease

One of the challenges in the growth of the global cytomegalovirus (CMV) therapeutics market is the asymptomatic nature of the disease. The poor diagnosis rate of the disease is expected to hinder the growth of the market during the forecast period.

For the detailed list of factors that will drive and challenge the growth of the cytomegalovirus (CMV) therapeutics market during 2019-2023, view our report.

Competitive Landscape

The market appears to be highly concentrated with the presence of a few market players. Vendors in the market are focusing on developing drugs in more than one form to provide treatment options and ensure the high efficacy of their drugs. This market research report will help clients identify new growth opportunities and design unique growth strategies by providing a comprehensive analysis of the market's competitive landscape and offering information on the products offered by companies.

Table of Contents
Product Code: IRTNTR31041

TABLE OF CONTENTS

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

  • 2.1 Preface
  • 2.2 Preface
  • 2.3 Currency conversion rates for US$

PART 03: MARKET LANDSCAPE

  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis

PART 04: MARKET SIZING

  • Market definition
  • Market sizing 2018
  • Market size and forecast 2018-2023

PART 05: FIVE FORCES ANALYSIS

  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

PART 06: PIPELINE

PART 07: MARKET SEGMENTATION BY ROA

  • Market segmentation by RoA
  • Comparison by RoA
  • Oral - Market size and forecast 2018-2023
  • Parenteral - Market size and forecast 2018-2023
  • Others - Market size and forecast 2018-2023
  • Market opportunity by RoA

PART 08: CUSTOMER LANDSCAPE

PART 09: GEOGRAPHIC LANDSCAPE

  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2018-2023
  • Europe - Market size and forecast 2018-2023
  • Asia - Market size and forecast 2018-2023
  • ROW - Market size and forecast 2018-2023
  • Key leading countries
  • Market opportunity

PART 10: DRIVERS AND CHALLENGES

  • Market drivers
  • Market challenges

PART 11: MARKET TRENDS

PART 12: VENDOR LANDSCAPE

  • Overview
  • Landscape disruption
  • Competitive scenario

PART 13: VENDOR ANALYSIS

  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • AstraZeneca
  • Bausch Health
  • F. Hoffmann-La Roche Ltd
  • Gilead Sciences, Inc.
  • Merck & Co., Inc.

PART 14: APPENDIX

  • Research methodology
  • List of abbreviations

PART 15: EXPLORE TECHNAVIO

List of Exhibits

  • Exhibit 01: Global pharmaceuticals market
  • Exhibit 02: Segments of global pharmaceuticals market
  • Exhibit 03: Market characteristics
  • Exhibit 04: Market segments
  • Exhibit 05: Market definition - Inclusions and exclusions checklist
  • Exhibit 06: Market size 2018
  • Exhibit 07: Global market: Size and forecast 2018-2023 ($ millions)
  • Exhibit 08: Global market: Year-over-year growth 2019-2023 (%)
  • Exhibit 09: Five forces analysis 2018
  • Exhibit 10: Five forces analysis 2023
  • Exhibit 11: Bargaining power of buyers
  • Exhibit 12: Bargaining power of suppliers
  • Exhibit 13: Threat of new entrants
  • Exhibit 14: Threat of substitutes
  • Exhibit 15: Threat of rivalry
  • Exhibit 16: Market condition - Five forces 2018
  • Exhibit 17: Global CMV therapeutics market pipeline: Overview
  • Exhibit 18: Global CMV therapeutics market pipeline: Overview
  • Exhibit 19: RoA - Market share 2018-2023 (%)
  • Exhibit 20: Comparison by RoA
  • Exhibit 21: Oral - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 22: Oral - Year-over-year growth 2019-2023 (%)
  • Exhibit 23: Parenteral - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 24: Parenteral - Year-over-year growth 2019-2023 (%)
  • Exhibit 25: Others - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 26: Others - Year-over-year growth 2019-2023 (%)
  • Exhibit 27: Market opportunity by RoA
  • Exhibit 28: Customer landscape
  • Exhibit 29: Market share by geography 2018-2023 (%)
  • Exhibit 30: Geographic comparison
  • Exhibit 31: North America - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 32: North America - Year-over-year growth 2019-2023 (%)
  • Exhibit 33: Top 3 countries in North America
  • Exhibit 34: Europe - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 35: Europe - Year-over-year growth 2019-2023 (%)
  • Exhibit 36: Top 3 countries in Europe
  • Exhibit 37: Asia - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 38: Asia - Year-over-year growth 2019-2023 (%)
  • Exhibit 39: Top 3 countries in Asia
  • Exhibit 40: ROW - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 41: ROW - Year-over-year growth 2019-2023 (%)
  • Exhibit 42: Top 3 countries in ROW
  • Exhibit 43: Key leading countries
  • Exhibit 44: Market opportunity
  • Exhibit 45: Impact of drivers and challenges
  • Exhibit 46: Vendor landscape
  • Exhibit 47: Landscape disruption
  • Exhibit 48: Vendors covered
  • Exhibit 49: Vendor classification
  • Exhibit 50: Market positioning of vendors
  • Exhibit 51: AstraZeneca - Vendor overview
  • Exhibit 52: AstraZeneca - Product segments
  • Exhibit 53: AstraZeneca - Organizational developments
  • Exhibit 54: AstraZeneca - Geographic focus
  • Exhibit 55: AstraZeneca - Key offerings
  • Exhibit 56: AstraZeneca - Key customers
  • Exhibit 57: Bausch Health - Vendor overview
  • Exhibit 58: Bausch Health - Business segments
  • Exhibit 59: Bausch Health - Organizational developments
  • Exhibit 60: Bausch Health - Geographic focus
  • Exhibit 61: Bausch Health - Segment focus
  • Exhibit 62: Bausch Health - Key offerings
  • Exhibit 63: Bausch Health - Key customers
  • Exhibit 64: F. Hoffmann-La Roche Ltd - Vendor overview
  • Exhibit 65: F. Hoffmann-La Roche Ltd - Business segments
  • Exhibit 66: F. Hoffmann-La Roche Ltd - Organizational developments
  • Exhibit 67: F. Hoffmann-La Roche Ltd - Geographic focus
  • Exhibit 68: F. Hoffmann-La Roche Ltd - Segment focus
  • Exhibit 69: F. Hoffmann-La Roche Ltd - Key offerings
  • Exhibit 70: F. Hoffmann-La Roche Ltd - Key customers
  • Exhibit 71: Gilead Sciences, Inc. - Vendor overview
  • Exhibit 72: Gilead Sciences, Inc. - Business segments
  • Exhibit 73: Gilead Sciences, Inc. - Organizational developments
  • Exhibit 74: Gilead Sciences, Inc. - Geographic focus
  • Exhibit 75: Gilead Sciences, Inc. - Key offerings
  • Exhibit 76: Gilead Sciences, Inc. - Key customers
  • Exhibit 77: Merck & Co., Inc. - Vendor overview
  • Exhibit 78: Merck & Co., Inc. - Business segments
  • Exhibit 79: Merck & Co., Inc. - Organizational developments
  • Exhibit 80: Merck & Co., Inc. - Geographic focus
  • Exhibit 81: Merck & Co., Inc. - Segment focus
  • Exhibit 82: Merck & Co., Inc. - Key offerings
  • Exhibit 83: Merck & Co., Inc. - Key customers
  • Exhibit 84: Validation techniques employed for market sizing
Back to Top